BioSpace News Archive

Chicago Children’s Advocacy Center (ChicagoCAC) is pleased to announce its new fall fundraiser, A Night of Heroes: Protecting Children. Battling Abuse. Restoring Lives. The event will be held at The Montgomery Club on Wednesday, Oct. 10 from 6 p.m. to 9 p.m.

Medidata today announced that it will release its third quarter 2018 financial results before the market opens on Thursday, October 18, 2018.

DNAnexus, the global leader in biomedical informatics and data management, today announced the winners of the Mosaic Community Challenge: Clinical Strain Detection, which evaluated the accuracy of microbial strain detection in metagenomic samples.

The only computer-generated and fully automated charge infusion coding solution in healthcare today is now available in the Epic App Orchard.

The More To Life Foundation announced today its upcoming experiential course in Houston, Texas to meet the growing demand from its regional chapter.

Adamas Pharmaceuticals, Inc. today announced that pooled Phase 3 data of GOCOVRI™ (amantadine) extended release capsules were published online in Parkinsonism and Related Disorders

As EMTs, paramedics, and other first responders continue to play an increasingly important role in saving lives and protecting communities, EMS World, a subsidiary of HMP, today announced the launch of a new EMS World website, designed to provide even more value for this critical audience.

Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced the publication of nonclinical data for PEGPH20 in Clinical Cancer Research, an American Association for Cancer Research (AACR) journal.

EaseCentral, the leading HR and benefits SaaS platform powered by insurance brokers, today announced a partnership with Oscar Health, a technology-driven, consumer-focused health insurer that makes it easier for patients to access and choose quality, affordable care.

Horizon Pharma plc (NASDAQ:HZNP) announced new data from the Phase 2 clinical trial of teprotumumab for people living with moderate-to-severe active thyroid eye disease (TED) showing a majority of patients that had reductions in proptosis at week 24 maintained these reductions 48 weeks following the study completion, or nearly a year off therapy.